Mitsuru Sugawara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mitsuru Sugawara has a total of 521 co-authors. Here are the top co-authors by number of shared publications:
Ken Iseki
Laboratory of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
67 shared publications- Yoh Takekuma
Department of Pharmacy, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060–8648, Japan
61 shared publications Katsumi Miyazaki
56 shared publicationsYoh Takekuma
Department of Pharmacy, Hokkaido University Hospital, Kita-ku, Sapporo, Japan
49 shared publicationsYoshitaka Saito
Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Japan
45 shared publicationsMichiya Kobayashi
Department of Pharmacy, Hokkaido University Hospital, Sapporo, Japan
40 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
Feasibility evaluation of parallel administration of nanoliposomal irinotecan and levofolinate in unresectable pancreatic cancer treatment
Background: Nanoliposomal irinotecan (nal-IRI) combined with levofolinate (l-LV) and fluorouracil (5-FU) is an effective second-line treatment for unresectable pancreatic cancer. The approved dosing schedule comprises sequential administration of premedication, nal-IRI (90 min), and l-LV (120 min), followed by 5-FU (46 h). This study evaluated the feasibility of parallel administration to shorten total infusion time by comparing parallel and sequential administration schedules. Methods: This retrospective study included patients who received the nal-IRI regimen between June 2020 and December 2024. Patients were divided into two groups according to the administration schedule: sequential administration (June to October 2020, n = 13) and parallel administration (November 2020 to December 2024, n = 98). The primary endpoint was the incidence of grade ≥ 3 neutropenia within 90 d of treatment initiation. Results: Grade ≥ 3 neutropenia occurred in 15.4% of patients in the sequential‑administration group and 39.8% in the parallel‑administration group (unadjusted odds ratio, 3.64; 95% confidence interval, 0.76–17.30; P = 0.13). The incidence in the first cycle was 7.7% and 8.2% between the groups ( P = 1.00). The incidences of other grade ≥ 3 and all-grade adverse events also did not differ significantly between the groups. The incidences of febrile neutropenia and fever did not differ significantly between the groups (febrile neutropenia: 7.7% vs. 7.1%, P = 1.00; fever: 46.2% vs. 25.5%, P = 0.18). The parallel-administration group had a disease control rate of 48.8%, which did not differ significantly from that of the sequential-administration group (33.3%; P = 0.37). Parallel administration reduced the daily bed occupancy time by approximately 150 min. Conclusions: Parallel administration of nal-IRI and l-LV may be operationally feasible for improving resource efficiency in outpatient chemotherapy units; however, its comparative safety relative to sequential administration remains uncertain because of imprecision in the effect estimates.
- 15 November 2026
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
Open AccessFeasibility evaluation of parallel administration of nanoliposomal irinotecan and levofolinate in unresectable pancreatic cancer treatment
Background: Nanoliposomal irinotecan (nal-IRI) combined with levofolinate (l-LV) and fluorouracil (5-FU) is an effective second-line treatment for unresectable pancreatic cancer. The approved dosing schedule comprises sequential administration of premedication, nal-IRI (90 min), and l-LV (120 min), followed by 5-FU (46 h). This study evaluated the feasibility of parallel administration to shorten total infusion time by comparing parallel and sequential administration schedules. Methods: This retrospective study included patients who received the nal-IRI regimen between June 2020 and December 2024. Patients were divided into two groups according to the administration schedule: sequential administration (June to October 2020, n = 13) and parallel administration (November 2020 to December 2024, n = 98). The primary endpoint was the incidence of grade ≥ 3 neutropenia within 90 d of treatment initiation. Results: Grade ≥ 3 neutropenia occurred in 15.4% of patients in the sequential‑administration group and 39.8% in the parallel‑administration group (unadjusted odds ratio, 3.64; 95% confidence interval, 0.76–17.30; P = 0.13). The incidence in the first cycle was 7.7% and 8.2% between the groups ( P = 1.00). The incidences of other grade ≥ 3 and all-grade adverse events also did not differ significantly between the groups. The incidences of febrile neutropenia and fever did not differ significantly between the groups (febrile neutropenia: 7.7% vs. 7.1%, P = 1.00; fever: 46.2% vs. 25.5%, P = 0.18). The parallel-administration group had a disease control rate of 48.8%, which did not differ significantly from that of the sequential-administration group (33.3%; P = 0.37). Parallel administration reduced the daily bed occupancy time by approximately 150 min. Conclusions: Parallel administration of nal-IRI and l-LV may be operationally feasible for improving resource efficiency in outpatient chemotherapy units; however, its comparative safety relative to sequential administration remains uncertain because of imprecision in the effect estimates.
- Open Access
- 6 November 2026
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
Familial juvenile hyperuricemic nephropathy requiring the use of febuxostat during the perinatal period: a case report including evaluation of transfer into cord blood and breast milk
Background: There are no case reports or epidemiological studies on the use of febuxostat, a drug used to treat hyperuricemia, during pregnancy or breastfeeding. We encountered a case of familial juvenile hyperuricemic nephropathy in which the patient required febuxostat during the perinatal period. This case provides valuable insights into placental and breast milk transfer of febuxostat. Case presentation: A 30-year-old woman presented with familial juvenile hyperuricemic nephropathy. She strongly desired to have children. She was found to be pregnant while her condition was being controlled with febuxostat 40 mg/day and sodium bicarbonate 500 mg/day. When pregnancy was confirmed, the patient was 9 weeks pregnant. Following consultation, febuxostat administration continued during pregnancy. The patient gave birth at 38 weeks of gestation. The maternal plasma concentration of febuxostat immediately prior to delivery (before medication) was 169 ng/mL, and the umbilical cord blood concentration at birth (4 h after medication) was 154 ng/mL. No major congenital abnormalities were observed at birth. The patient chose to breastfeed after delivery. She continued taking 40 mg/day of febuxostat orally. Febuxostat concentrations in breast milk immediately before dosing and at 1, 3.5, 7 h after dosing were 37, 40, 58, and 81 ng/mL, respectively. At the one-month checkup, a deformity of the infant’s second toenail was noted. However, its association with a congenital malformation could not be confirmed, and there were no functional abnormalities. No problems with the infant’s growth or development were observed. Conclusion: The patient continued to febuxostat throughout pregnancy and subsequently gave birth. Further data are required to draw conclusions regarding the risks to infants associated with febuxostat use during the perinatal period.
- 6 November 2026
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
Open AccessFamilial juvenile hyperuricemic nephropathy requiring the use of febuxostat during the perinatal period: a case report including evaluation of transfer into cord blood and breast milk
Background: There are no case reports or epidemiological studies on the use of febuxostat, a drug used to treat hyperuricemia, during pregnancy or breastfeeding. We encountered a case of familial juvenile hyperuricemic nephropathy in which the patient required febuxostat during the perinatal period. This case provides valuable insights into placental and breast milk transfer of febuxostat. Case presentation: A 30-year-old woman presented with familial juvenile hyperuricemic nephropathy. She strongly desired to have children. She was found to be pregnant while her condition was being controlled with febuxostat 40 mg/day and sodium bicarbonate 500 mg/day. When pregnancy was confirmed, the patient was 9 weeks pregnant. Following consultation, febuxostat administration continued during pregnancy. The patient gave birth at 38 weeks of gestation. The maternal plasma concentration of febuxostat immediately prior to delivery (before medication) was 169 ng/mL, and the umbilical cord blood concentration at birth (4 h after medication) was 154 ng/mL. No major congenital abnormalities were observed at birth. The patient chose to breastfeed after delivery. She continued taking 40 mg/day of febuxostat orally. Febuxostat concentrations in breast milk immediately before dosing and at 1, 3.5, 7 h after dosing were 37, 40, 58, and 81 ng/mL, respectively. At the one-month checkup, a deformity of the infant’s second toenail was noted. However, its association with a congenital malformation could not be confirmed, and there were no functional abnormalities. No problems with the infant’s growth or development were observed. Conclusion: The patient continued to febuxostat throughout pregnancy and subsequently gave birth. Further data are required to draw conclusions regarding the risks to infants associated with febuxostat use during the perinatal period.
- Open Access
- 7 October 2026
- Published by American Society of Hematology in Blood Advances
Alveolar distribution of ruxolitinib in pulmonary alveolar proteinosis developing during the treatment of chronic GVHD
- 7 October 2026
- Published by American Society of Hematology in Blood Advances
Open AccessAlveolar distribution of ruxolitinib in pulmonary alveolar proteinosis developing during the treatment of chronic GVHD
- 11 May 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (6) , e70153
Hyperfiltration in Critically Ill Older Adults: Incidence, Risk Factors, Time Course, and Predictive Performance of Kidney Function Estimation
Study Objective: This study aimed to evaluate the incidence, associated risk factors, time course, and predictive performance of kidney function estimation equations for hyperfiltration in critically ill older adults. Methods: This retrospective observational study evaluated 325 patients (median age, 76 years) admitted to the intensive care unit (ICU) of a tertiary‐care university hospital, for a total of 2934 patient‐days. The hyperfiltration threshold was defined using measured creatinine clearance (Clcr) > −0.883 × age + 167.398. Independent factors associated with hyperfiltration were identified via a multivariable logistic regression model, and time to onset and duration were evaluated using Kaplan–Meier curves. Additionally, the predictive performance of the measured Clcr was assessed using the Cockcroft–Gault equation. Bias was analyzed using the Bland–Altman analysis, and accuracy was evaluated using the percentage within 30% of the measured Clcr (P30). Results: Hyperfiltration occurred in 56% of the patients. Risk factors included male sex, high body mass index, trauma‐related admission, vasopressor use, and low serum creatinine levels. The median time from ICU admission to hyperfiltration onset was 5 days, and the median duration of hyperfiltration episodes was 8 days. The Cockcroft–Gault equation substantially underestimated measured Clcr in patients with hyperfiltration. Even among those whose measured Clcr did not meet the conventional augmented renal clearance (ARC) threshold (> 130 mL/min), the equation exhibited a clinically significant negative bias (−35 mL/min) with limited accuracy (P30: 39%). This underestimation was even more pronounced in patients meeting the ARC criteria (bias: −62 mL/min; P30: 27%). Conclusions: Hyperfiltration is highly prevalent in critically ill older adults. The Cockcroft–Gault equation substantially underestimated actual kidney function, even without meeting the ARC criteria. Continuous monitoring of the measured Clcr is recommended to avoid inappropriate medication dose reductions due to underestimation. image
- 11 May 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (6) , e70153
Hyperfiltration in Critically Ill Older Adults: Incidence, Risk Factors, Time Course, and Predictive Performance of Kidney Function Estimation
Study Objective: This study aimed to evaluate the incidence, associated risk factors, time course, and predictive performance of kidney function estimation equations for hyperfiltration in critically ill older adults. Methods: This retrospective observational study evaluated 325 patients (median age, 76 years) admitted to the intensive care unit (ICU) of a tertiary‐care university hospital, for a total of 2934 patient‐days. The hyperfiltration threshold was defined using measured creatinine clearance (Clcr) > −0.883 × age + 167.398. Independent factors associated with hyperfiltration were identified via a multivariable logistic regression model, and time to onset and duration were evaluated using Kaplan–Meier curves. Additionally, the predictive performance of the measured Clcr was assessed using the Cockcroft–Gault equation. Bias was analyzed using the Bland–Altman analysis, and accuracy was evaluated using the percentage within 30% of the measured Clcr (P30). Results: Hyperfiltration occurred in 56% of the patients. Risk factors included male sex, high body mass index, trauma‐related admission, vasopressor use, and low serum creatinine levels. The median time from ICU admission to hyperfiltration onset was 5 days, and the median duration of hyperfiltration episodes was 8 days. The Cockcroft–Gault equation substantially underestimated measured Clcr in patients with hyperfiltration. Even among those whose measured Clcr did not meet the conventional augmented renal clearance (ARC) threshold (> 130 mL/min), the equation exhibited a clinically significant negative bias (−35 mL/min) with limited accuracy (P30: 39%). This underestimation was even more pronounced in patients meeting the ARC criteria (bias: −62 mL/min; P30: 27%). Conclusions: Hyperfiltration is highly prevalent in critically ill older adults. The Cockcroft–Gault equation substantially underestimated actual kidney function, even without meeting the ARC criteria. Continuous monitoring of the measured Clcr is recommended to avoid inappropriate medication dose reductions due to underestimation. image
- 6 April 2026
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (6) , 609-617
Impact of time to antibiotic optimization following inadequate or excessive empiric therapy on clinical outcomes
Objective: Inadequate empiric therapy for sepsis has been correlated with heightened mortality; however, bloodstream infections do not uniformly manifest as severe presentations. Empiric administration of broad-spectrum antibiotics may result in adverse events and treatment failure. This study aimed to evaluate the impact of time to antibiotic optimization on outcomes of patients with bloodstream infections who received either inadequate or excessive empiric therapy. Methods: This single-center retrospective study included patients aged ≥18 years with positive blood culture results and confirmed antimicrobial susceptibility between April 2018 and March 2024. The primary endpoint was a composite outcome of all-cause 30-day mortality, microbiological failure, and antibiotic modification due to insufficient efficacy. The secondary endpoints included adverse event–related discontinuation in the excessive group. Results: Of the 1943 patients screened, 405 met the inclusion criteria. In the inadequate group ( n = 150), antimicrobial stewardship team intervention was associated with treatment success (OR, 0.38; 95% CI, 0.15–0.90; P = .028), whereas time to optimization was not associated with any of the outcomes. In the excessive group ( n = 255), delayed optimization (≥64 h) was a risk factor for treatment failure (OR, 2.63; 95% CI, 1.14–6.07; P = .023). Later optimization (≥100 h) was also linked to higher antibiotic discontinuation due to adverse events. Conclusion: Delayed optimization was independently associated with adverse outcomes in cohorts receiving excessive empiric therapy. These findings emphasize the importance of prompt de-escalation of broad-spectrum antibiotics to mitigate treatment failure and treatment discontinuation attributable to adverse events.
- 6 April 2026
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (6) , 609-617
Impact of time to antibiotic optimization following inadequate or excessive empiric therapy on clinical outcomes
Objective: Inadequate empiric therapy for sepsis has been correlated with heightened mortality; however, bloodstream infections do not uniformly manifest as severe presentations. Empiric administration of broad-spectrum antibiotics may result in adverse events and treatment failure. This study aimed to evaluate the impact of time to antibiotic optimization on outcomes of patients with bloodstream infections who received either inadequate or excessive empiric therapy. Methods: This single-center retrospective study included patients aged ≥18 years with positive blood culture results and confirmed antimicrobial susceptibility between April 2018 and March 2024. The primary endpoint was a composite outcome of all-cause 30-day mortality, microbiological failure, and antibiotic modification due to insufficient efficacy. The secondary endpoints included adverse event–related discontinuation in the excessive group. Results: Of the 1943 patients screened, 405 met the inclusion criteria. In the inadequate group ( n = 150), antimicrobial stewardship team intervention was associated with treatment success (OR, 0.38; 95% CI, 0.15–0.90; P = .028), whereas time to optimization was not associated with any of the outcomes. In the excessive group ( n = 255), delayed optimization (≥64 h) was a risk factor for treatment failure (OR, 2.63; 95% CI, 1.14–6.07; P = .023). Later optimization (≥100 h) was also linked to higher antibiotic discontinuation due to adverse events. Conclusion: Delayed optimization was independently associated with adverse outcomes in cohorts receiving excessive empiric therapy. These findings emphasize the importance of prompt de-escalation of broad-spectrum antibiotics to mitigate treatment failure and treatment discontinuation attributable to adverse events.
- 19 January 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (2) , 107
Preventive effect of hot compress on phlebitis during cisplatin and Vinorelbine treatment for non-small cell lung cancer
Background Vinorelbine (VNR) is a key chemotherapeutic agent for treating non-small cell lung cancer (NSCLC). However, peripheral venous administration frequently induces phlebitis in 20–50% of patients. A previous study showed that applying a hot compress during VNR was effective in patients who had already developed symptoms. Therefore, this method was applied to all patients receiving VNR via peripheral venous administration at Hokkaido University Hospital. Herein, we aimed to evaluate the prophylactic efficacy of hot compresses for VNR-induced phlebitis in real-world settings. Methods Patients with NSCLC who received cisplatin (CDDP) + VNR (n = 92) were retrospectively evaluated. Patients were divided into a hot compress group, which included patients who received hot compresses during VNR administration, and a control group that did not receive hot compresses. The primary endpoint was the frequency of phlebitis during the first cycle between the groups. Results Hot compress significantly reduced the frequency of phlebitis during the first cycle (47.3% and 18.9% in the control and hot compress groups, respectively; P = 0.008) and on day 8 of the first cycle (38.2% and 10.8%; P = 0.004), with primary endpoint accomplishment. Furthermore, symptom reduction using hot compresses was confirmed among patients who received VNR on day 8 via a different arm from that administered on day 1 (31.6% vs. 3.0%, P = 0.002). Additionally, the onset of the first occurrence of VNR-induced phlebitis was significantly delayed (P = 0.008). Conclusion Hot compresses significantly reduced the frequency of VNR-induced phlebitis in patients with NSCLC receiving CDDP + VNR.
- 19 January 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (2) , 107
Preventive effect of hot compress on phlebitis during cisplatin and Vinorelbine treatment for non-small cell lung cancer
Background Vinorelbine (VNR) is a key chemotherapeutic agent for treating non-small cell lung cancer (NSCLC). However, peripheral venous administration frequently induces phlebitis in 20–50% of patients. A previous study showed that applying a hot compress during VNR was effective in patients who had already developed symptoms. Therefore, this method was applied to all patients receiving VNR via peripheral venous administration at Hokkaido University Hospital. Herein, we aimed to evaluate the prophylactic efficacy of hot compresses for VNR-induced phlebitis in real-world settings. Methods Patients with NSCLC who received cisplatin (CDDP) + VNR (n = 92) were retrospectively evaluated. Patients were divided into a hot compress group, which included patients who received hot compresses during VNR administration, and a control group that did not receive hot compresses. The primary endpoint was the frequency of phlebitis during the first cycle between the groups. Results Hot compress significantly reduced the frequency of phlebitis during the first cycle (47.3% and 18.9% in the control and hot compress groups, respectively; P = 0.008) and on day 8 of the first cycle (38.2% and 10.8%; P = 0.004), with primary endpoint accomplishment. Furthermore, symptom reduction using hot compresses was confirmed among patients who received VNR on day 8 via a different arm from that administered on day 1 (31.6% vs. 3.0%, P = 0.002). Additionally, the onset of the first occurrence of VNR-induced phlebitis was significantly delayed (P = 0.008). Conclusion Hot compresses significantly reduced the frequency of VNR-induced phlebitis in patients with NSCLC receiving CDDP + VNR.
- Open Access
- 22 December 2025
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 11 (1) , 110
Successful re-administration after nano-liposomal irinotecan-induced severe hypersensitivity reaction: a case report
Background: Nano-liposomal irinotecan (nal-IRI) combined with 5-fluorouracil (5-FU) and levofolinate has been reported to extend the survival of patients with pancreatic cancer and represents an effective second-line treatment. Nal-IRI encapsulates IRI in liposomes modified with polyethylene glycol (PEGylation), which can lead to infusion reactions. Hypersensitivity reactions (HSR) to chemotherapeutic agents include both allergic and infusion reactions, which are difficult to distinguish. Severe HSR can be fatal; however, discontinuation of the suspected drug directly affects the treatment strategy. We report a case of severe HSR during the first nal-IRI administration, in which treatment was successfully continued with supportive management. Case presentation: A woman in her early 80s with metastatic pancreatic cancer received nal-IRI + 5-FU + levofolinate as second-line treatment. Five minutes after the initiation of the first nal-IRI infusion, the patient developed a tightening sensation in the head, respiratory distress, convulsions, and loss of consciousness, with percutaneous oxygen saturation dropping to the 80% range. The nal-IRI infusion was immediately discontinued, and emergency management was initiated with intravenous infusion of hydrocortisone, famotidine, d-chlorpheniramine maleate, and oxygen administration, resulting in symptom improvement. Given the limited treatment options for metastatic pancreatic cancer and the patient’s strong desire to continue therapy, we decided to re-administer the regimen with intensified management, increasing dexamethasone to 19.8 mg and adding famotidine 20 mg and d-chlorpheniramine maleate 5 mg. Furthermore, we adopted a three-step dose-escalation method. The infusion was started at one-third of the standard rate, increased to two-thirds after 30 min, and finally adjusted to the full rate after another 30 min, after confirming the absence of HSR symptoms. Consequently, the patient did not exhibit any signs of HSR, and the same administration method was continued for 11 cycles until disease progression. Conclusions: The novelty of this report lies in presenting, for the first time, the detailed course and process by which treatment was successfully continued in a patient experiencing severe HSR upon initial nal-IRI administration, through enhanced supportive care tailored to the characteristics of the drug and stepwise dose adjustment.
- 22 December 2025
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 11 (1) , 110
Open AccessSuccessful re-administration after nano-liposomal irinotecan-induced severe hypersensitivity reaction: a case report
Background: Nano-liposomal irinotecan (nal-IRI) combined with 5-fluorouracil (5-FU) and levofolinate has been reported to extend the survival of patients with pancreatic cancer and represents an effective second-line treatment. Nal-IRI encapsulates IRI in liposomes modified with polyethylene glycol (PEGylation), which can lead to infusion reactions. Hypersensitivity reactions (HSR) to chemotherapeutic agents include both allergic and infusion reactions, which are difficult to distinguish. Severe HSR can be fatal; however, discontinuation of the suspected drug directly affects the treatment strategy. We report a case of severe HSR during the first nal-IRI administration, in which treatment was successfully continued with supportive management. Case presentation: A woman in her early 80s with metastatic pancreatic cancer received nal-IRI + 5-FU + levofolinate as second-line treatment. Five minutes after the initiation of the first nal-IRI infusion, the patient developed a tightening sensation in the head, respiratory distress, convulsions, and loss of consciousness, with percutaneous oxygen saturation dropping to the 80% range. The nal-IRI infusion was immediately discontinued, and emergency management was initiated with intravenous infusion of hydrocortisone, famotidine, d-chlorpheniramine maleate, and oxygen administration, resulting in symptom improvement. Given the limited treatment options for metastatic pancreatic cancer and the patient’s strong desire to continue therapy, we decided to re-administer the regimen with intensified management, increasing dexamethasone to 19.8 mg and adding famotidine 20 mg and d-chlorpheniramine maleate 5 mg. Furthermore, we adopted a three-step dose-escalation method. The infusion was started at one-third of the standard rate, increased to two-thirds after 30 min, and finally adjusted to the full rate after another 30 min, after confirming the absence of HSR symptoms. Consequently, the patient did not exhibit any signs of HSR, and the same administration method was continued for 11 cycles until disease progression. Conclusions: The novelty of this report lies in presenting, for the first time, the detailed course and process by which treatment was successfully continued in a patient experiencing severe HSR upon initial nal-IRI administration, through enhanced supportive care tailored to the characteristics of the drug and stepwise dose adjustment.
- Open Access
- 4 July 2025
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 11 (1) , 1-8
Temporary hypocalcemia induced by cetuximab sarotalocan without hypomagnesemia in a patient with hypoparathyroidism: a novel case report
Background: Cetuximab sarotalocan, which utilizes the light-activatable dye IRDye700Dx conjugated with cetuximab, is a first-in-class drug based on photoimmunotherapy for treating recurrent head and neck squamous cell carcinoma. Cetuximab frequently induces hypomagnesemia and secondary hypocalcemia. Herein, we report a case of independent hypocalcemia without hypomagnesemia during treatment and discuss symptom progression. Case Presentation: A female patient with left epipharyngeal cancer, hypothyroidism, and hypoparathyroidism was treated with cetuximab and sarotalocan. On day 3, serum-adjusted calcium levels decreased from 9.6 to 7.4 mg/dL, increased to 8.2 mg/dL on day 9, and further increased to 8.8 mg/dL on day 27; serum magnesium levels were not evaluated. After the second administration, serum-adjusted calcium levels decreased two days later, fluctuating between 7.6 and 8.1 mg/dL for three weeks. Serum magnesium levels were within the normal range, with no significant variation detected during the second cycle. A similar symptom course was observed during the third cycle. The patient received enteral nutrition daily with 424.8–1,038.4 mg of calcium, with daily adjustment during the administration, except on day 2. She received peripheral intravenous nutrition for several days after tumor illumination. Concomitant medications did not appear to affect serum calcium levels. Considering the case process and previous reports, we hypothesized that concomitant hypoparathyroidism, in addition to reduced calcium intake due to the treatment, may have contributed to the observed reduction. Conclusions: Hypocalcemia without hypomagnesemia can occur in patients with hypoparathyroidism receiving near-infrared photoimmunotherapy with cetuximab sarotalocan. The precise mechanisms and epidemiological features warrant further investigations.
- 4 July 2025
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 11 (1) , 1-8
Open AccessTemporary hypocalcemia induced by cetuximab sarotalocan without hypomagnesemia in a patient with hypoparathyroidism: a novel case report
Background: Cetuximab sarotalocan, which utilizes the light-activatable dye IRDye700Dx conjugated with cetuximab, is a first-in-class drug based on photoimmunotherapy for treating recurrent head and neck squamous cell carcinoma. Cetuximab frequently induces hypomagnesemia and secondary hypocalcemia. Herein, we report a case of independent hypocalcemia without hypomagnesemia during treatment and discuss symptom progression. Case Presentation: A female patient with left epipharyngeal cancer, hypothyroidism, and hypoparathyroidism was treated with cetuximab and sarotalocan. On day 3, serum-adjusted calcium levels decreased from 9.6 to 7.4 mg/dL, increased to 8.2 mg/dL on day 9, and further increased to 8.8 mg/dL on day 27; serum magnesium levels were not evaluated. After the second administration, serum-adjusted calcium levels decreased two days later, fluctuating between 7.6 and 8.1 mg/dL for three weeks. Serum magnesium levels were within the normal range, with no significant variation detected during the second cycle. A similar symptom course was observed during the third cycle. The patient received enteral nutrition daily with 424.8–1,038.4 mg of calcium, with daily adjustment during the administration, except on day 2. She received peripheral intravenous nutrition for several days after tumor illumination. Concomitant medications did not appear to affect serum calcium levels. Considering the case process and previous reports, we hypothesized that concomitant hypoparathyroidism, in addition to reduced calcium intake due to the treatment, may have contributed to the observed reduction. Conclusions: Hypocalcemia without hypomagnesemia can occur in patients with hypoparathyroidism receiving near-infrared photoimmunotherapy with cetuximab sarotalocan. The precise mechanisms and epidemiological features warrant further investigations.
- 7 April 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (5) , 1-8
Dexamethasone dose-dependently attenuates docetaxel-induced peripheral neuropathy in breast cancer treatment
Purpose Peripheral neuropathy is one of the most problematic adverse effects of docetaxel. We previously reported that dexamethasone (DEX) prevents taxane-associated acute pain syndrome (T-APS) in a dose-dependent manner, which might be a partial manifestation of chemotherapy-induced peripheral neuropathy (CIPN), in breast cancer treatment. Therefore, this study examined the dose-dependent prophylactic efficacy of DEX against CIPN. Methods Female patients with breast cancer receiving docetaxel-containing treatments (75 mg/m2) were divided into two groups according to DEX dosage on days 2–4; an 8 mg group (n = 56) and a 4 mg group (n = 28) and retrospectively evaluated. The primary endpoint in this study was defined as the development of grade ≥ 2 CIPN during 4 cycles of the treatment. Results The incidence of grade ≥ 2 CIPN was 32.1% in the 4 mg group and 10.7% in the 8 mg group and was significantly lower in the 8 mg group (P = 0.03). The incidence of all-grade CIPN was lower in the 8 mg group than in the control group, although the difference was not statistically significant (P = 0.06). Onset time of all-grade and grade ≥ 2 CIPN in the 8 mg group was significantly delayed compared to that in the 4 mg group (P = 0.003 and 0.01, respectively). Additionally, 8 mg/day of DEX was identified as a preventive factor for all-grade CIPN, although the evaluation of grade ≥ 2 symptoms was not possible. Conclusion Our study found that DEX attenuated docetaxel-induced CIPN in a dose-dependent manner during real-world breast cancer treatment. Further studies are needed to develop better CIPN management strategies.
- 7 April 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (5) , 1-8
Dexamethasone dose-dependently attenuates docetaxel-induced peripheral neuropathy in breast cancer treatment
Purpose Peripheral neuropathy is one of the most problematic adverse effects of docetaxel. We previously reported that dexamethasone (DEX) prevents taxane-associated acute pain syndrome (T-APS) in a dose-dependent manner, which might be a partial manifestation of chemotherapy-induced peripheral neuropathy (CIPN), in breast cancer treatment. Therefore, this study examined the dose-dependent prophylactic efficacy of DEX against CIPN. Methods Female patients with breast cancer receiving docetaxel-containing treatments (75 mg/m2) were divided into two groups according to DEX dosage on days 2–4; an 8 mg group (n = 56) and a 4 mg group (n = 28) and retrospectively evaluated. The primary endpoint in this study was defined as the development of grade ≥ 2 CIPN during 4 cycles of the treatment. Results The incidence of grade ≥ 2 CIPN was 32.1% in the 4 mg group and 10.7% in the 8 mg group and was significantly lower in the 8 mg group (P = 0.03). The incidence of all-grade CIPN was lower in the 8 mg group than in the control group, although the difference was not statistically significant (P = 0.06). Onset time of all-grade and grade ≥ 2 CIPN in the 8 mg group was significantly delayed compared to that in the 4 mg group (P = 0.003 and 0.01, respectively). Additionally, 8 mg/day of DEX was identified as a preventive factor for all-grade CIPN, although the evaluation of grade ≥ 2 symptoms was not possible. Conclusion Our study found that DEX attenuated docetaxel-induced CIPN in a dose-dependent manner during real-world breast cancer treatment. Further studies are needed to develop better CIPN management strategies.
- Open Access
- 1 January 2025
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 18 (1) , 151-158
Severe Hypomagnesemia in a Patient Treated Using Carboplatin Co-Administered with Vonoprazan
Introduction: We describe a case of severe hypomagnesemia that occurred during treatment with carboplatin (CBDCA) and nanoparticle albumin-bound paclitaxel (nab-PTX) for lung adenocarcinoma when co-administered with vonoprazan. Case Presentation: A man in his 70s was diagnosed with stage IIIA lung adenocarcinoma and received CBDCA and nab-PTX as the first-line treatment. The patient had been taking omeprazole 10 mg once daily (for >3 years) for gastroesophageal reflux disease, but it was switched to lansoprazole 15 mg because of hospital’s adopted medication. During the first treatment cycle, his serum creatinine levels increased from 1.0 to 1.5 mg/dL, suggesting CBDCA-associated renal impairment. Because of gastric discomfort on day 15 of the second cycle, lansoprazole was switched to vonoprazan 10 mg once daily. On day 23 of the second cycle, he developed torsades de pointes and was hospitalized; severe hypomagnesemia (0.4 mg/dL) was detected to be causing the symptoms. Discontinuation of vonoprazan and a single intravenous infusion of 60 mEq magnesium sulfate raised serum magnesium levels to 3.7 mg/dL, and the arrhythmia disappeared. Mild hypomagnesemia (1.4 mg/dL) reappeared 5 days later, and an additional intravenous infusion of 20 mEq magnesium sulfate with subsequent oral magnesium oxide (1,980 mg/day) resolved the symptoms. CBDCA was discontinued and nab-PTX monotherapy was continued. Vonoprazan was resumed owing to gastric discomfort relapse; however, grade ≥2 hypomagnesemia did not reappear later. Conclusions: This case highlights the risk of severe hypomagnesemia in patients with CBDCA and vonoprazan co-administration; therefore, regular monitoring of serum magnesium levels during the treatment is crucial.
- 1 January 2025
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 18 (1) , 151-158
Open AccessSevere Hypomagnesemia in a Patient Treated Using Carboplatin Co-Administered with Vonoprazan
Introduction: We describe a case of severe hypomagnesemia that occurred during treatment with carboplatin (CBDCA) and nanoparticle albumin-bound paclitaxel (nab-PTX) for lung adenocarcinoma when co-administered with vonoprazan. Case Presentation: A man in his 70s was diagnosed with stage IIIA lung adenocarcinoma and received CBDCA and nab-PTX as the first-line treatment. The patient had been taking omeprazole 10 mg once daily (for >3 years) for gastroesophageal reflux disease, but it was switched to lansoprazole 15 mg because of hospital’s adopted medication. During the first treatment cycle, his serum creatinine levels increased from 1.0 to 1.5 mg/dL, suggesting CBDCA-associated renal impairment. Because of gastric discomfort on day 15 of the second cycle, lansoprazole was switched to vonoprazan 10 mg once daily. On day 23 of the second cycle, he developed torsades de pointes and was hospitalized; severe hypomagnesemia (0.4 mg/dL) was detected to be causing the symptoms. Discontinuation of vonoprazan and a single intravenous infusion of 60 mEq magnesium sulfate raised serum magnesium levels to 3.7 mg/dL, and the arrhythmia disappeared. Mild hypomagnesemia (1.4 mg/dL) reappeared 5 days later, and an additional intravenous infusion of 20 mEq magnesium sulfate with subsequent oral magnesium oxide (1,980 mg/day) resolved the symptoms. CBDCA was discontinued and nab-PTX monotherapy was continued. Vonoprazan was resumed owing to gastric discomfort relapse; however, grade ≥2 hypomagnesemia did not reappear later. Conclusions: This case highlights the risk of severe hypomagnesemia in patients with CBDCA and vonoprazan co-administration; therefore, regular monitoring of serum magnesium levels during the treatment is crucial.